title: The ARSACS phenotype can include supranuclear gaze palsy and skin lipofuscin deposits.
authors.forename: James C
authors.initials: JC
authors.lastname: Stevens
authors.forename: Sinéad M
authors.initials: SM
authors.lastname: Murphy
authors.forename: Indran
authors.initials: I
authors.lastname: Davagnanam
authors.forename: Rahul
authors.initials: R
authors.lastname: Phadke
authors.forename: Glenn
authors.initials: G
authors.lastname: Anderson
authors.forename: Suran
authors.initials: S
authors.lastname: Nethisinghe
authors.forename: Fion
authors.initials: F
authors.lastname: Bremner
authors.forename: Paola
authors.initials: P
authors.lastname: Giunti
authors.forename: Mary M
authors.initials: MM
authors.lastname: Reilly
mesh_terms: D000328:Adult; D006801:Humans; D008062:Lipofuscin / Q000378:metabolism*; D008297:Male; D009128:Muscle Spasticity / Q000150:complications* / Q000378:metabolism*; D010641:Phenotype; D012867:Skin / Q000378:metabolism*; D020754:Spinocerebellar Ataxias / Q000150:complications / Q000151:congenital* / Q000378:metabolism; D013494:Supranuclear Palsy, Progressive / Q000150:complications* / Q000378:metabolism*
chemical_list: D008062:Lipofuscin